<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123652</url>
  </required_header>
  <id_info>
    <org_study_id>16124-11:10:3610-082018</org_study_id>
    <nct_id>NCT04123652</nct_id>
  </id_info>
  <brief_title>Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain</brief_title>
  <official_title>Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: an Observational Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allevio Pain Management Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allevio Pain Management Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      As lidocaine and ketamine provide analgesia by acting on different molecular pathways,
      administering them together may produce synergistic effects, which can allow for using a
      lower dose of each medication and thereby reducing the corresponding side effects. To the
      investigator's knowledge, despite the common practice of multimodal analgesia,
      lidocaine-ketamine infusions have never been studied prospectively in an out of hospital
      setting to treat neuropathic pain. The aim of the present study is to evaluate the
      effectiveness of the current routine practice of lidocaine-ketamine infusions conducted at
      Allevio Pain Management Clinic, a large outpatient community based chronic pain management
      facility. Lidocaine-ketamine infusions are prescribed to patients that have pain that is
      considered to be neuropathic for which standard anti-neuropathic medications have been
      ineffective or poorly tolerated by patients. A prospective longitudinal study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives

        1. To evaluate effectiveness of lidocaine-ketamine infusions in reducing neuropathic pain,
           as assessed using the Revised Pain Quality Assessment Scale (PQAS-R) and Short Form
           Brief Pain Inventory (BPI-SF).

        2. To evaluate the effects of lidocaine-ketamine infusions on the measures of Global
           Improvement and Satisfaction Score, Pain Self-Efficacy Questionnaire (PSEQ), Pain
           Catastrophic Scale (PCS), Beck Depression Inventory (BDI), and Patient self-reported
           perceived duration of effect (PSPDE).

        3. To assess, analyze, and report adverse events

      The study will be conducted per IMMPACT recommendations (17). Multi variable parameters will
      be captured: pain unpleasantness, physical function, emotional function, global improvement
      and satisfaction with treatment, adverse events and disposition. Additional instruments will
      be used in the triage process and follow-up (S-LANSS, PSEQ).

      Number of subjects: all eligible consecutive patients accepted for lidocaine-ketamine
      infusions over period of 6 months.

      Patients with multi focal and/or non-dermatomal pain with neuropathic component will be
      included.

      Dosing and infusion orders are completed by one of the physician-investigators prior to
      patient arrival based on body weight, and modified if required after individual evaluation.
      Based on published literature and clinical impression, higher doses seem to be more effective
      and result in longer pain relief. Therefore, subsequent infusion doses will be increased to
      the maximally tolerated doses (i.e. minimal side effects).

      Doses will be calculated using the following:

        -  Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to
           maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion
           based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.

        -  Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded
           to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg)
           each infusion based on tolerability of side effects.

      Standard clinic procedure will be followed for completing the infusions and managing side
      effects. The infusion will be initiated at 360 ml/hour for planned completion in 45 minutes,
      rate adjusted if side effects develop. Total doses of medication are recorded in the medical
      record.

      Data collection and Management All study tools will be completed by patients online using, or
      in the clinic RedCap system. RedCap is a mature, secure web application for building and
      managing online surveys and databases (Vanderbilt University). The system is secured by SSL
      protocol and data is encrypted. Patients will be contacted via Email with a secure link to
      RedCap database, or if they would not be able to do it at home research, they can complete
      the questionnaires with research coordinator's assistant in secure computers at the clinic.
      Participant will receive reminders about upcoming visits and promoted to complete the
      follow-up forms. Allevio data protection is also SSL enabled and secured by SHA256, and they
      are issued by Rapid SSL and purchased through Ceerts4Less.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients are assessed for eligibility on their first visit (screening visit); additional visits may be required to address patient questions and collect baseline data. Qualified participants will be scheduled for their 5 infusions at 8 week intervals.
Dosing and infusion orders are completed by one of the physician-investigators prior to patient arrival based on body weight, and modified if required after individual evaluation. Based on published literature and clinical impression, higher doses seem to be more effective and result in longer pain relief. Therefore, subsequent infusion doses will be increased to the maximally tolerated doses (i.e. minimal side effects).
Participants will be asked to complete the follow-up questionnaires every four weeks starting from their first infusion up to 8 times. On their last study visit, 4 weeks following the last infusion, participants will have an exit interview in addition to completing study measures.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of effectiveness of lidocaine-ketamine infusions: PQAS-R</measure>
    <time_frame>4 weeks after the first infusion and every 4 weeks up to 36 weeks</time_frame>
    <description>Primary outcome measure: relative change on the PQAS-R. Moderate clinically important improvement is considered as 30% reduction (Dworkin et al., 2008)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine infusion on BDI</measure>
    <time_frame>Baseline to end-of-study every 4 weeks up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on Beck's Depression Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine infusion on PGIC</measure>
    <time_frame>Baseline to end-of-study every 4 weeks up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on Pain Global Improvement and Satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine infusion on BPI</measure>
    <time_frame>Baseline to end-of-study every 4 weeks up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on Brief Pain Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine infusion on PQAS-R</measure>
    <time_frame>Baseline to end-of-study every 4 weeks up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on Revised Pain Quality Assessment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine infusion on PSEQ</measure>
    <time_frame>Baseline to end-of-study every 4 weeks up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on Patient Self-Efficacy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine infusion on PCS</measure>
    <time_frame>Baseline to end-of-study every 4 weeks up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on Pain Catastrophizing Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine infusion on PSPDE</measure>
    <time_frame>Baseline to end-of-study every 4 weeks up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on viii. Patient self-reported perceived duration of effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lidocaine and ketamine on narcotic consumption</measure>
    <time_frame>Baseline to end-of-study up to 36 weeks</time_frame>
    <description>Effect of lidocaine and ketamine infusion on narcotic consumption</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Neuropathic Pain and Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Lidocaine and ketamine infusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992</intervention_name>
    <description>An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.
• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours.</description>
    <arm_group_label>Lidocaine and ketamine infusion</arm_group_label>
    <other_name>ketamine Hydrochloride, Serial# 5751304560, DIN 02246796</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pain duration &gt; 3 months;

        Multifocal and/or non-dermatomal neuropathic pain per Pain Diagram;

        Failed medical management with at least 2 neuromodulation agents (e.g., gabapentinoids,
        antidepressants, cannabinoids);

        Neuropathic component (12 or more points on S-LANSS);

        Exclusion Criteria:

        Non-English speakers;

        Refusal to sign informed consent;

        Allergy to ketamine and/or lidocaine;

        Known relative contraindications to ketamine use which include poorly controlled systemic
        illnesses: hypertension, hyperthyroidism, ischemic heart disease, heart failure,
        psychiatric comorbidity (e.g., psychosis, schizophrenia, dissociative state);

        Known contraindication to lidocaine use which include current symptomatic or clinically
        significant brady- or tachyarrhythmia, systolic blood pressure &lt;90 or &gt;180 mmHg;

        Scheduled interventions targeting neuropathic pain: epidural injections, peripheral nerve
        blocks, Bier block, radiofrequency of dorsal root ganglia and peripheral nerves, additional
        lidocaine or ketamine infusions;

        Newly added analgesic or neuromodulating medications within 30 days;

        Recently performed neuromodulating interventions within 90 days;

        Previous lidocaine-ketamine, lidocaine or ketamine infusion within 6 months;

        Acute intoxication or active illegal substance abuse;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramin Safakish, MD.FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allevio Pain Management Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramin Safakish, MD. FRCPC</last_name>
    <phone>6474788462</phone>
    <email>Ramin.Safakish@AllevioClinic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shadi Babazadeh, MD</last_name>
    <phone>6474788462</phone>
    <phone_ext>90</phone_ext>
    <email>Shadi.Babazadeh@AllevioClinic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Allevio Pain Management Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin Safakish, MD. FRCPC</last_name>
      <phone>6474788462</phone>
      <email>Ramin.Safakish@AllevioClinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Shadi Babazadeh, MD</last_name>
      <phone>6474788462</phone>
      <phone_ext>90</phone_ext>
      <email>shadi.Babazadeh@AllevioClinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ramin Safakish, MD. FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imrat Sohanpal, MD. FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul Pathak, MD. FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Khetani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Praveen Ganty, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Mirdamadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shadi Babazadeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andriy Strilchuk, MD. NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. Epub 2007 Dec 11.</citation>
    <PMID>18055266</PMID>
  </reference>
  <results_reference>
    <citation>BONICA JJ. The management of pain of cancer. J Mich State Med Soc. 1953 Mar;52(3):284-90.</citation>
    <PMID>13035388</PMID>
  </results_reference>
  <results_reference>
    <citation>Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2. Erratum in: Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added].</citation>
    <PMID>23245607</PMID>
  </results_reference>
  <results_reference>
    <citation>IASP. (2003). How Prevalent Is Chronic Pain? International Association for the Study of Pain. Retrieved from https://www.iasp-pain.org/files/Content/ContentFolders/Publications2/PainClinicalUpdates/Archives/PCU03-2_1390265045864_38.pdf</citation>
  </results_reference>
  <results_reference>
    <citation>Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011 Oct 6;11:770. doi: 10.1186/1471-2458-11-770.</citation>
    <PMID>21978149</PMID>
  </results_reference>
  <results_reference>
    <citation>Cho SK, Heiby EM, McCracken LM, Moon DE, Lee JH. Daily functioning in chronic pain: study of structural relations with posttraumatic stress disorder symptoms, pain intensity, and pain avoidance. Korean J Pain. 2011 Mar;24(1):13-21. doi: 10.3344/kjp.2011.24.1.13. Epub 2011 Feb 25.</citation>
    <PMID>21390174</PMID>
  </results_reference>
  <results_reference>
    <citation>Wahl AK, Rustøen T, Rokne B, Lerdal A, Knudsen Ø, Miaskowski C, Moum T. The complexity of the relationship between chronic pain and quality of life: a study of the general Norwegian population. Qual Life Res. 2009 Oct;18(8):971-80. doi: 10.1007/s11136-009-9515-x. Epub 2009 Aug 18.</citation>
    <PMID>19688608</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012 Aug;13(8):715-24. doi: 10.1016/j.jpain.2012.03.009. Epub 2012 May 16.</citation>
    <PMID>22607834</PMID>
  </results_reference>
  <results_reference>
    <citation>Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz. 2016 Feb;30(1):47-61. doi: 10.1007/s00482-015-0084-3. Review.</citation>
    <PMID>26767993</PMID>
  </results_reference>
  <results_reference>
    <citation>Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003 Nov 13;349(20):1943-53. Review.</citation>
    <PMID>14614170</PMID>
  </results_reference>
  <results_reference>
    <citation>Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006605. doi: 10.1002/14651858.CD006605.pub2. Review.</citation>
    <PMID>20091598</PMID>
  </results_reference>
  <results_reference>
    <citation>IASP. (1994). Part III: Pain Terms, A Current List with Definitions and Notes on Usage. In Classification of Chronic Pain (second ed., pp. 209-214): IASP Press. Retrieved from</citation>
  </results_reference>
  <results_reference>
    <citation>van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014 Apr;155(4):654-62. doi: 10.1016/j.pain.2013.11.013. Epub 2013 Nov 26. Review. Erratum in: Pain. 2014 Sep;155(9):1907.</citation>
    <PMID>24291734</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell, J. N., &amp; Meyer, R. A. (2006). Mechanisms of neuropathic pain. Neuron, 52(1), 77-92. doi:10.1016/j.neuron.2006.09.021 CDC. (2017a). Opioid Overdose. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/drugoverdose/index.html CDC. (2017b). Prescribing Data. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/drugoverdose/data/prescribing.html</citation>
  </results_reference>
  <results_reference>
    <citation>Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006 Aug 1;175(3):265-75. Review.</citation>
    <PMID>16880448</PMID>
  </results_reference>
  <results_reference>
    <citation>Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014 Feb;77(2):357-67. doi: 10.1111/bcp.12094. Review.</citation>
    <PMID>23432384</PMID>
  </results_reference>
  <results_reference>
    <citation>Dale R, Stacey B. Multimodal Treatment of Chronic Pain. Med Clin North Am. 2016 Jan;100(1):55-64. doi: 10.1016/j.mcna.2015.08.012. Epub 2015 Oct 17. Review.</citation>
    <PMID>26614719</PMID>
  </results_reference>
  <results_reference>
    <citation>Rogers M, Tang L, Madge DJ, Stevens EB. The role of sodium channels in neuropathic pain. Semin Cell Dev Biol. 2006 Oct;17(5):571-81. Epub 2006 Oct 28. Review.</citation>
    <PMID>17123847</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou HY, Chen SR, Pan HL. Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011 May;4(3):379-88. Review.</citation>
    <PMID>21686074</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic pain</keyword>
  <keyword>Fibromyalgia</keyword>
  <keyword>Lidocaine infusion</keyword>
  <keyword>Ketamine infusion</keyword>
  <keyword>Chronic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

